Examining HPV infections and vaccine attitudes among Slovenian women
Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination
This study is trying to see if offering the HPV vaccine along with screenings can help improve vaccination rates and reduce HPV infections among women in Slovenia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | N/A to 35 Years |
| Sex | Female |
| Sponsor | University Medical Centre Ljubljana Academic / other |
| Locations | 1 site (Ljubljana, Municipality of Domžale) |
| Trial ID | NCT06995157 on ClinicalTrials.gov |
What this trial studies
This study investigates the characteristics of HPV infections and the attitudes towards HPV vaccination among women in Slovenia following the introduction of the HPV vaccine. It aims to address the low vaccination uptake and improve cervical cancer screening rates by targeting women who are in between vaccinated and unvaccinated cohorts. The study will offer the HPV vaccine to eligible participants while simultaneously conducting HPV screenings to assess the effectiveness of this combined approach. The findings could inform public health strategies to enhance vaccination coverage and reduce HPV transmission.
Who should consider this trial
Good fit: Ideal candidates for this study are Slovenian women who are eligible for cervical cancer screening and have not been vaccinated against HPV.
Not a fit: Patients who are currently pregnant, experiencing menstrual bleeding, or have undergone a hysterectomy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to increased HPV vaccination rates and improved cervical cancer screening, ultimately reducing the incidence of cervical cancer.
How similar studies have performed: Previous studies in Sweden have shown success with similar combined interventions, indicating a potential for effective outcomes in this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * regular cervical smear (CS) every 3 years after a previously normal CS result, first CS at entry into the ZORA screening program, second CS one year after entering the ZORA screening program following a previously normal first CS, control CS after a pathological cytological result or after a non-neoplastic cytological result or after conization or laser vaporization of the cervix, and curative CS due to signs or pathological clinical findings Exclusion Criteria: * pregnancy at the time of the gynecological examination, menstrual bleeding at the time of the gynecological examination, inflammation of the vagina and/or cervix at the time of the gynecological examination, other medical and clinical conditions that prevent the taking of a CS, condition after hysterectomy, already taken CS for the purpose of the present study, and hypersensitivity to the active substances or any excipient of the HPV vaccine
Where this trial is running
Ljubljana, Municipality of Domžale
- UMC Ljubljana — Ljubljana, Municipality of Domžale, Slovenia (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.